Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 14,006 shares at $363.58 ($5.1M) on 2019-11-26, disclosed to the SEC on 2019-11-26.
Open-market sale of $5.1M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $362.75 | 5,994 | $2.2M | 42.7% |
| 2 | $363.58 | 1,422 | $517K | 10.2% |
| 3 | $363.58 | 1,422 | $517K | 10.2% |
| 4 | $364.20 | 2,284 | $832K | 16.3% |
| 5 | $364.20 | 2,284 | $832K | 16.3% |
| 6 | $365.41 | 300 |
| $110K |
| 2.2% |
| 7 | $365.41 | 300 | $110K | 2.2% |
| Total | $363.51 avg | 14,006 | $5.1M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |